Mesalamine* (Mesalamine) — Medicare Part D spending
Multiple manufacturers (20) · Rank #179 by total Part D spend · CMS data year 2023
Medicare Part D spent $271,604,425 on Mesalamine* (Mesalamine) in 2023, the #179 drug by total Part D spending out of 3,598 drugs. That worked out to about $4.90 per dosage unit, $705 per claim and $2,853 per beneficiary, across 385,045 claims for 95,185 beneficiaries. Average spending per dosage unit fell -8.5% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Mesalamine* (Mesalamine) spending at a glance (2023)
| Metric | Mesalamine* (Mesalamine) |
|---|---|
| Total Part D spending (2023) | $271,604,425 |
| Total spending (2022) | $271,488,581 |
| Year-over-year change in total spending | +0.0% |
| Average spending per dosage unit (2023) | $4.90 |
| Change in spend per dosage unit (YoY) | -8.5% |
| Avg annual change per dosage unit (2019-2023 CAGR) | -7.7% |
| Average spending per claim (2023) | $705 |
| Average spending per beneficiary (2023) | $2,853 |
| Total claims (2023) | 385,045 |
| Beneficiaries (2023) | 95,185 |
| Total dosage units (2023) | 88,673,543 |
| Manufacturer(s) | Multiple manufacturers (20) |
| National rank by total spend (of 3,598 drugs) | #179 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $271,488,581 | $271,604,425 | +0.0% |
| Avg spend per dosage unit | $5.36 | $4.90 | -8.5% |
| Avg spend per claim | $721 | $705 | — |
| Avg spend per beneficiary | $2,973 | $2,853 | — |
| Total claims | 376,771 | 385,045 | — |
| Beneficiaries | 91,315 | 95,185 | — |
How Mesalamine* compares with nearby drugs
Drugs with total Part D spending closest to Mesalamine* (Mesalamine):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Mesalamine* (Mesalamine) (this drug, #179) | $271,604,425 | $4.90 | -8.5% |
| Aristada (Aripiprazole Lauroxil) (#177) | $272,878,291 | $980.72 | +3.7% |
| Prezcobix (Darunavir/Cobicistat) (#178) | $271,838,024 | $83.83 | +7.4% |
| Kerendia (Finerenone) (#180) | $269,681,549 | $22.00 | +7.1% |
| Enbrel Mini (Etanercept) (#181) | $269,006,301 | $1,837.74 | +9.9% |
| Rytary (Carbidopa/Levodopa) (#182) | $266,869,488 | $4.49 | +8.7% |
Frequently asked questions
How much does Medicare Part D spend on Mesalamine*?
Medicare Part D spent $271,604,425 on Mesalamine* (Mesalamine) in 2023 (the latest CMS data year), across 385,045 claims for 95,185 beneficiaries. That ranks #179 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Mesalamine*?
In 2023, the weighted average Medicare Part D spending per dosage unit for Mesalamine* (Mesalamine) was $4.90. Compared with 2022 it fell -8.5%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Mesalamine*?
CMS attributes Mesalamine* (Mesalamine) to Multiple manufacturers (20) in the 2023 Part D spending file. Average spending per claim was $705 and per beneficiary $2,853.
Is the Mesalamine* figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20